ND-2110

ND-2110 is an **experimental small-molecule inhibitor of interleukin-1 receptor-associated kinase 4** designed to bind the ATP pocket of IRAK4 with reported nanomolar potency. Preclinical reports describe selective IRAK4 inhibition and activity in models relevant to **MYD88 L265P-mutant activated B cell-like diffuse large B cell lymphoma**, as well as inflammatory disease models including lipopolysaccharide-induced TNF production, collagen-induced arthritis, and gout. Publicly available information identifies it primarily as a research-stage compound disclosed in patent literature and conference presentations, and a specific commercial developer or brand name has not been clearly established from the provided context.